14 registrations that name niacin as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 14 registrations
Status
Phase
12US sites across 8 states
1
2 to 4
5 to 19
20 or more
All 14 registrations
RecruitingNCT05452772
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
Phase 2
Johns Hopkins University
About 66 people
Started Nov 1, 2023
In plain words A Phase 2 study of niacin in people 21 and older, run by Johns Hopkins University. It plans to enroll about 66 people at 3 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 21 and older; healthy volunteers accepted. Conditions: Tobacco Use Disorder.
21 years old or older
Be a daily smoker (minimum of 5 cigarettes/day on a typical day and breath CO of 6 or greater at screening) with multiple unsuccessful previous quit attempts, and report a continued desire to quit smoking
Read, write, and speak English
Agree to abstain from smoking for the psilocybin/niacin session from 1 hour before psilocybin/niacin administration until at least 8 hours afterward
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Psilocybin; Niacin
Registered summary
This is a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. Four sites with experience in conducting psilocybin research will be involved in this trial: Johns Hopkins University (JHU), the University of Alabama at Birmingham (UAB), and New York University (NYU). The full summary is on the listing.
Where, as registered
3 US sites in 3 states.
RecruitingNCT05398484
Psilocybin Therapy in Advanced Cancer
Phase 2 and 3
NYU Langone Health
About 200 people
Started May 24, 2023
In plain words A Phase 2 and 3 study of niacin in people 21 to 100, run by NYU Langone Health. It plans to enroll about 200 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 100. Conditions: Advanced Cancer.
Aged ≥ 21
Diagnosis of Advanced Cancer defined as:
Solid tumors to include stage 3 or 4, metastatic illness, or recurrent illness
Hematologic malignancies to include, but not limited to, Stage 3 or 4 non-Hodgkins lymphoma, late-stage multiple myeloma or second-line therapy for multiple myeloma, and all forms of acute myeloid leukemia
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Psilocybin 25 mgs; Niacin 100mg; Psychotherapy
Registered summary
The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existential distress (i.e., loss of meaning and hope; fear of death) in advanced cancer (i.e., stage 3 or 4). Study medications will be administered in conjunction with brief psychotherapy that is designed to treat anxiety, depression and existential distress in advanced cancer.
Where, as registered
2 US sites in 2 states.
RecruitingNCT06983730
The Kidney's Response to Exercise in Heat, and the Impact of Vitamin B3 on This Response
Early phase 1
Beth Israel Deaconess Medical Center
About 28 people
Started Jan 26, 2026
In plain words An early phase 1 study of niacin in people 18 to 45, run by Beth Israel Deaconess Medical Center. It plans to enroll about 28 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45; healthy volunteers accepted. Conditions: Heat Strain; Healthy Volunteer Study; Kidney Dysfunction.
Healthy volunteer
Any race
Estimated glomerular filtration rate greater than 90 ml/min/1.73m2
Urine albumin/creatinine ratio less than 30mg/g
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Vitamin B3
Registered summary
The goal of this clinical trial is to learn about the processes occurring in the kidneys while under heat stress in healthy volunteers. The main questions it aims to answer are: * How do the chemicals produced by the body change under conditions of higher versus lower heat stress? * What role does a specific area of the body's metabolism, known as NAD+ metabolism, play in the body's response to heat stress, and can this response be modified by taking vitamin B3?
Where, as registered
2 US sites in 1 state.
RecruitingNCT03540758
Regulation of Endogenous Glucose Production by Central KATP Channels
Phase 2
Albert Einstein College of Medicine
About 100 people
Started Aug 1, 2018
In plain words A Phase 2 study of niacin in people 21 to 70, run by Albert Einstein College of Medicine. It plans to enroll about 100 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 70; healthy volunteers accepted. Conditions: Diabetes Mellitus; Glucose Metabolism Disorders.
Age: 21-70 years old
Body Mass Index (BMI) under 40 kg/m\^2
Negative drug screen (see below)
Normal Hemoglobin A1c (HbA1c) and fasting glucose
8 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Diazoxide; Nicotinic acid; Placebo
Registered summary
Type 2 diabetes (T2D) affects the ability of the body to process glucose (sugar). Under fasting conditions, the liver is able to make sugar to maintain glucose levels in an important process called endogenous glucose production (EGP). Previous studies suggest that the central nervous system (CNS), including the brain, helps to regulate levels of glucose in the body by communicating with the liver. This process can be impaired in people with type 2 diabetes, and can contribute to the high level of glucose seen in these individuals. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06200155
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
Phase 2
M.D. Anderson Cancer Center
About 48 people
Started Apr 16, 2024
In plain words A Phase 2 study of niacin in people 25 and older, run by M.D. Anderson Cancer Center. It plans to enroll about 48 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 25 and older. Conditions: Depression, Anxiety; Psilocybin-Assisted Psychotherapy; Advanced Cancer.
Participants must have one of the following histology documented tumor types: non-small cell lung carcinoma, renal cell carcinoma, urothelial carcinoma, prostate cancer, head and neck squamous cell carcinoma, ovarian cancer, breast cancer,…
Documentation of locally advanced, recurrent, or metastatic incurable malignancy that has partially responded or progressed after at least 1 available standard therapy and disease is stable (no progression of disease for 3 months or more…
No prior grade 3 AEs on current standard of care cancer treatment regimen;
Age ≥ 25 years; as by the age of 25 brain is fully developed.
11 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Psilocybin; Niacin
Registered summary
To learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy on depression and/or anxiety in participants who are being treated for advanced cancer.
Where, as registered
1 US site in 1 state.
RecruitingNCT06175403
A Study of Niacin Regulation
Early phase 1
Mayo Clinic
About 32 people
Started Jan 1, 2024
In plain words An early phase 1 study of niacin in people 18 to 65, run by Mayo Clinic. It plans to enroll about 32 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65; healthy volunteers accepted. Conditions: Excessive Weight Gain.
Males and females between 18 and 65 years of age who are able to comprehend instructions, follow study procedures, willing to sign an informed consent form, and consume an isoenergetic diet eating all meals from Mayo CRTU for at least 3…
Overweight/Obese volunteers will have a BMI 29.0 - 40.0 kg/m2.
Upper body/visceral obesity (UBO) in women will be defined as those with a waist-hip ratio (WHR) > 0.85 and/or increased visceral fat by single slice CT scan, usually with > 120 cm2 of visceral fat by CT scanning or a visceral fat/total…
Female subjects are eligible if they meet the following criteria: are not pregnant or nursing; all women of childbearing potential will have a negative urine pregnancy test at screening and a negative urine pregnancy test within 48 hours…
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Niacin
Registered summary
Adults who gain most of their excess weight in the abdominal area typically do not respond to things that "turn off" fat cells the same way as lean people. The researchers are trying to understand why fat tissue responds differently in people with different body types.
Where, as registered
1 US site in 1 state.
RecruitingNCT06858332
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
Observational
Novartis Pharmaceuticals
About 2,382 people
Started Apr 15, 2025
In plain words An observational study of niacin in people 18 to 99, run by Novartis Pharmaceuticals. It plans to enroll about 2,382 people at 20 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 99. Conditions: Atherosclerotic Cardiovascular Disease.
Written informed consent (signed and dated).
Males and females aged ≥18 years.
Presence of one of the following ASCVDs for at least 3 months within the 2 years prior to signing the informed consent to participate in this study:
history of MI;
4 more inclusion criteria and the exclusion criteria are on the listing.
This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this parameter and the cardiovascular disease (CVD) risk.
Where, as registered
No US site; Russia (20).
RecruitingNCT06991712
Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients
Phase 2
Christopher Kai Shun Leung
About 138 people
Started May 19, 2025
In plain words A Phase 2 study of niacin in people 18 and older, run by Christopher Kai Shun Leung. It plans to enroll about 138 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Glaucoma.
glaucoma patients
age ≥ 18 years
best corrected VA ≥20/40
IOP <21 mmHg
1 more inclusion criterion and the exclusion criteria are on the listing.
The goal of this clinical trial is to determine whether oral supplementation with different nicotinamide adenine dinucleotide (NAD) precursors can improve visual function in adults with primary open-angle glaucoma. The main questions it aims to answer are: 1. Does daily oral administration of equimolar doses of nicotinamide riboside (NR), nicotinamide (NAM), nicotinamide mononucleotide (NMN), or nicotinic acid (NA) improve visual field sensitivity in glaucoma patients over the short term? 2. The full summary is on the listing.
Where, as registered
No US site; Hong Kong (1).
RecruitingNCT07732166
Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.
Early phase 1
Pontifícia Universidade Católica do Rio de Janeiro
About 100 people
Started Apr 1, 2026
In plain words An early phase 1 study of niacin in people 21 to 60, run by Pontifícia Universidade Católica do Rio de Janeiro. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 60; healthy volunteers accepted. Conditions: Healthy Adults.
Minimum age of 21 and maximum age of 60;
Minimum of eight years of schooling;
Fluency in Portuguese;
Agree, one week before the experiment, to abstain from:
13 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Psilocybin (Usona Institute); Niacin 100 mg
Registered summary
Self-awareness, the capacity of becoming the object of one's own awareness, is a frontier of scientific knowledge. Over centuries, distinct philosophical and religious traditions have grappled with the subject, but only recently has the importance of self-awareness been established as a central concept for scientific investigation, to which scientific methods can be applied to explore and characterize this phenomenon. Self-awareness has important implications, notably from a clinical perspective. The full summary is on the listing.
Where, as registered
No US site; Brazil (1).
RecruitingNCT05934409
Adipose Tissue Storage in the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery
No phase
Université de Sherbrooke
About 40 people
Started Nov 1, 2023
In plain words A study of niacin in people 18 to 65, run by Université de Sherbrooke. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65; healthy volunteers accepted. Conditions: Diabetes Mellitus Type 2.
Aged 18 to 65
BMI 35 kg/m2
Diagnosed T2D - according to Diabetes Canada diagnostics criteria.
Diagnosed non-T2D - according to Diabetes Canada diagnostics criteria.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Bariatric surgery; Nicotinic Acid
Registered summary
The present protocol aims to understand and establish whether there is a causal link between adipose tissue metabolic remodeling and Type 2 Diabetes (T2D) remission after bariatric surgery. All participants will have a bariatric surgery, divided in 2 groups: with or without T2D.
Where, as registered
No US site; Canada (1).
RecruitingNCT06843148
Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
No phase
Université de Sherbrooke
About 36 people
Started Jun 22, 2026
In plain words A study of niacin in people 20 to 80, run by Université de Sherbrooke. It plans to enroll about 36 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 20 to 80. Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD); Liver Fibrosis/NASH; Non-Alcoholic Steato-Hepatitis (NASH).
aged 20 to 80 years;
diagnosed with MASLD, defined as the presence of liver steatosis + abdominal obesity (as defined by the International Diabetes Federation country/ethnic group-specific criteria;
The exclusion criteria are on the listing.
What it tests, as registered
Niacin (250mg); Placebo Oral Tablet
Registered summary
Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation/ fibrosis. MASLD results from fat being disproportionately deposited in the liver. The goal of this mechanistic study is to investigate metabolic response in patients aged 20 to 80 years with non-alcoholic fatty liver disease, after niacin (vitamin B3) treatment. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
Not yet recruitingNCT07306364
Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain
Phase 2
Yale University
About 45 people
Starts Oct 2026 (estimated)
In plain words A Phase 2 study of niacin in people 18 to 65, run by Yale University. It plans to enroll about 45 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65; healthy volunteers accepted. Conditions: Chronic Low Back Pain (CLBP); Physical Therapy; Psilocybin.
1\. Ability to provide informed consent in English.
2\. Provision of signed and dated informed consent form.
3\. Stated willingness to comply with all study procedures and availability for the duration of the study.
4\. Male and female participants aged 18-65 years.
14 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Psilocybin 10 mg; Psilocybin 25 mg; Niacin 100 mg
Registered summary
The purpose of this research study is to investigate whether a single administration of psilocybin can improve interoceptive awareness (awareness of bodily sensations) in individuals with chronic low back pain undergoing physical therapy, and whether these improvements are linked to pain relief and better physical therapy outcomes.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT06760533
Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)
Early phase 1
NYU Langone Health
About 10 people
Starts Aug 2026 (estimated)
In plain words An early phase 1 study of niacin in people 18 to 75, run by NYU Langone Health. It plans to enroll about 10 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: IBS - Irritable Bowel Syndrome.
Severe IBS patients meeting Rome IV criteria. Severe IBS is defined by IBS-SS >300, or one or more emergency room (ER) visit for abdominal pain in the last year.
This study will serve as a pilot randomized controlled trial to assess the feasibility of Psilocybin-Assisted Psychotherapy (PAP) in Treating Irritable Bowel Syndrome (IBS). Patients with severe IBS will undergo 3 pre-psychotherapy sessions with two licensed and trained psychedelic therapists, then will be randomized to undergo a guided psychotherapy session with single 25 mg oral "high" dose of psilocybin or a single 100 mg dose of niacin (active placebo) and attend 4 post-therapy integration sessions.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07004725
Therapy of Niacin for Rheumatoid Arthritis
Phase 2
Peking University People's Hospital
About 60 people
Starts May 28, 2025 (estimated)
In plain words A Phase 2 study of niacin in people 18 and older, run by Peking University People's Hospital. It plans to enroll about 60 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Rheumatoid Arthritis (RA).
Male or female ≥18 years of age at the time of screening, weight≥35 kg.
Diagnosed with rheumatoid arthritis satisfying the 1987 American College of Rheumatology classification criteria or ACR/EULAR 2010 classification criteria.
Stable treatment, including DMARDs (disease-modifying anti-rheumatic drugs) and glucocorticoids, was stable in dose for at least 4 weeks, and no biological agents were used during the first 12 weeks of enrollment.
Dyslipidemia (5.2≤TC≤7.2mmol/L, 3.4≤LDL-c≤4.9mmol/L or 1.7≤TG≤5.1 mmol/L)
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
niacin sustained release capsules; Placebo
Registered summary
This study is a study to evaluate the safety and efficacy of administering niacin sustained-release capsules to rheumatoid arthritis with hyperlipidemia patients. Sixty patients were randomly assigned to niacin or placebo for 12 weeks, followed by niacin for 12 weeks. Changes in disease activity score, immune cell subtypes, markers of intestinal damage, intestinal flora, and other laboratory indicators will be monitored.